WuXi Venture Fund Managing Director Sofie Qiao On Taking Risks: An Interview With PharmAsia News
This article was originally published in PharmAsia News
WuXi AppTec Inc. has largely invested along with established venture funds since its launch in 2011 backed by $50 million of investor funds. But the humble student aims to evolve and invest more boldly, says newly appointed managing director Sofie Qiao.
You may also be interested in...
From Biologics To Corporate Venture, China's Leading CRO Continues To Evolve
In an effort to boost its biological capabilities and continue its march into additional integrated services, China's leading contract research organization WuXi PharmaTech has acquired Abgent Inc., a provider of biological research agent products and services
China Micron Ban Not Cause For Further Health Sector Worry?
China has taken a new counterstrike against the US in the chips sector, but the risk of potential wider impact on the biopharma sector appears to be limited given other tighter regulations already in place.
'Being Innovative Not Enough': Multinationals Want Driver‘s Seat In Changing China
Multinational pharma firms are exploring their next growth trajectories in China, where some including AstraZeneca and Roche are deepening their commitment by becoming further integrated into local innovation ecosystems and pursuing deals, while others such as Pfizer are focusing on tackling reimbursement challenges.